Goat Anti-Mouse IgG Fab-BIOT
Katalog-Nummer 1015-08
Size : 1.0mg
Marke : Southern Biotech
Contact local distributor :
Telefonnummer : +1 850 650 7790
| Isotype | Goat IgG |
|---|---|
| Isotype Control | Goat IgG-BIOT |
| Specificity | Reacts with the Fab region of mouse IgG1, IgG2a, IgG2b, IgG2c, and IgG3 |
| Source | Pooled antisera from goat hyperimmunized with mouse IgG |
| Cross Adsorption | Mouse IgG Fc; may react with immunoglobulins from other species and the light chains of other mouse immunoglobulins |
| Purification Method | Affinity chromatography on mouse IgG Fab covalently linked to agarose |
| Conjugate | BIOT (Biotin) |
| Buffer Formulation | Phosphate buffered saline containing < 0.1% sodium azide |
| Clonality | Polyclonal |
| Concentration | 0.5 mg/mL |
| Volume | 2.0 mL |
| Recommended Storage | 2-8°C |
| Applications | Quality tested applications for relevant formats include - ELISA 1-4 FLISA |
| RRID Number | AB_2794195 |
Documentation
Technical Bulletin Safety Datasheet
Certificate of Analysis Lookup
Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view
- 1. Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33:5578-87. (ELISA)
- 2. Alving CR, Beck Z, inventors; The Government of the United states of America as Represented by the Secretary of the Army, assignee. Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin. United States patent application publication US 2017/0182152 A1. 2017 Jun 29. (ELISA)
- 3. Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J Control Release. 2018;275:12-19. (ELISA)
- 4. Lee J, Park E, Min J, Sung S, Jang Y, Shin JS, et al. Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. Nucleic Acids Res. 2018;46:1635-47. (ELISA)